This is a non-interventional primary use of data study utilizing de-identified patient-level onboarding and adherence data managed through the MSGo patient support service platform and includes a sub-study to explore the impact of ofatumumab on relevant patient reported outcomes (PROs) with respect to clinical outcomes.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Part I and II: Proportion of doses not completed within three days of the expected date
Timeframe: Initiation
Part I and II: Proportion of doses not completed within 3 days of the expected date
Timeframe: First 3 months of maintenance